Tenax Therapeutics, Inc. has completed enrollment for its Phase 3 clinical trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results